Delivery Order SPE2DB22D2218-SPE2DB25FR3DD
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen injectors valued at $7,550.30 under a firm fixed price contract. The award was made on July 21, 2025, with an ultimate completion date of July 22, 2025, and represents a non-set-aside competitive award. AmerisourceBergen will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $39.7K delivery order to AmerisourceBergen Drug Corp for DUPIXENT (dupilumab) 300 mg/2 mL pen injectors on August 19, 2025, with an ultimate completion date of August 20, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The delivery will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $14,097.56 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 ml pen injectors on August 14, 2025, with an ultimate completion date of August 15, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. DUPIXENT (dupilumab) is a biologic immunosuppressant medication used to treat...
- The Defense Logistics Agency awarded a $68,986.58 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on July 30, 2025, with an ultimate completion date of July 31, 2025. This non-competitive delivery order represents a firm fixed price transaction under an existing Indefinite Delivery Contract vehicle. The place of performance is AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to...
- The Defense Logistics Agency awarded a $14,397.15 delivery order to AmerisourceBergen Drug Corp for DUPIXENT 300 mg/2 ml pen auto-injectors. The contract, finalized on August 12, 2025, with completion targeted for August 13, 2025, utilizes firm fixed pricing with no set-aside designation, indicating competitive award through open solicitation. Performance will be executed from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's headquarters. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $7,646.70 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen auto-injectors on July 24, 2025, with completion scheduled for July 25, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat eczema, asthma, and other...
- The Defense Logistics Agency awarded a delivery order valued at $12,879.52 to AmerisourceBergen Drug Corp for DUPIXENT 300 MG/2 ML pen auto-injectors on August 8, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is listed as Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $8,747.93 to AmerisourceBergen Drug Corp for the supply of DUPIXENT 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform at its corporate office location. This delivery order falls under the company's broader...
- The Defense Logistics Agency awarded a $3,418.92 firm fixed-price delivery order to AmerisourceBergen Drug Corp for supply of DUPIXENT 200 mg/1.14 ml pen injectors, with an ultimate completion date of August 12, 2025. This non-set-aside award represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA Troop Support Medical. The product will be performed at the contractor's location in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $10,813.19 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on August 13, 2025, with an ultimate completion date of August 14, 2025. This is a firm fixed price, competitively awarded delivery order with no set-aside designation. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe eczema, asthma, and...
- SPE2DB22D2218Indefinite Delivery Contract
- SPE2DB22D2218-SPE2DB25FR3DDDelivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $6,716.90 for DUPIXENT 200 mg/1.14 ml pen auto-injectors on August 11, 2025, with completion scheduled for August 12, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive pharmaceutical supply vehicle running through December 2026 that enables the contractor to provide a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, serves as a critical federal medical procurement vendor specializing in brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. DUPIXENT (dupilumab) is a biologic immunosuppressant used to treat moderate-to-severe eczema, asthma, and other inflammatory conditions, with this order supporting Defense Health Agency and broader military healthcare system requirements. The contractor's demonstrated capability to fulfill federal procurement requirements through open competition, combined with its extensive portfolio of medical product deliveries to DLA and military healthcare systems, positions it as a key vendor for pharmaceutical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.7k | 8/11/25 |